MiRNA Scientific

A differentiated urine test for prostate cancer today and a molecular platform connecting cancer biology with precision medicine. miR Sentinel uses a 48-target urinary exosomal small RNA panel to assess high-grade prostate cancer risk — no rectal exam or blood draw. FDA Breakthrough Device Designation, a 1,379-man prospective clinical program and an in-house CLIA/CAP laboratory.